



April 14, 2026

**National Stock Exchange of India Limited**

The Listing Department  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex  
Bandra (East), Mumbai 400051  
Maharashtra, India

NSE Symbol: IKS

**Sub: Clarification on news item titled “Jhunjunwala-backed IKS Healthcare looks to acquire TruBridge for \$600 million”**

Dear Sir/Ma’am,

This is with reference to your email dated April 13, 2026 seeking clarification on the news item published on April 13, 2026 in The Economic Times. In this regard, set forth below is our response:

- (a) **Whether such negotiations/events were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations/events till date.**

We would like to clarify that the Company regularly evaluates strategic opportunities in the ordinary course of business, including bidding for potential strategic transactions through its subsidiaries, with or without exclusivity, such as in the captioned news. In furtherance to the foregoing, one of the wholly owned subsidiaries of the Company participated in discussions with TruBridge, Inc. in relation to a potential acquisition of TruBridge. As on date, no definitive or binding agreements have been executed for such potential transaction. The aforesaid discussions remain non-binding and are subject to various contingencies, including ongoing negotiations, requisite approvals (including board approvals) and execution of definitive agreements. There can be no assurance that any transaction will be consummated or as to the terms or timing thereof. The Company will make appropriate disclosures only as and when there are material developments requiring disclosure under the applicable regulations.

- (b) **Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.**

The Company confirms that there is no information which is required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that has not already been disclosed to the stock exchanges.

M/s. Inventurus Knowledge Solutions Limited

801, Building No. 5 & 6, 8th Floor, Mindspace Business Park (SEZ), Thane - Belapur Road, Airoli, Navi Mumbai - 400 708, Thane, Maharashtra, India. | Board: +91 22 3071 1100 | Fax: 91 22 6646 6879 | info@ikshealth.in | [www.ikshealth.com](http://www.ikshealth.com)



**(c) Material impact of the article on the Company**

At this stage, the Company is unable to ascertain the material impact of the said news item. The Company will make appropriate disclosures in accordance with applicable law, as and when required.

We kindly request you to take the above clarification on your record. The Company remains fully committed to compliance and will continue to promptly disclose any material information to the Exchanges in accordance with regulatory requirements.

Thanking you.

Yours sincerely,  
**Inventurus Knowledge Solutions Limited**

**Sameer Chavan**  
**Company Secretary and Compliance Officer**  
Membership No. F7211